Analysis and data insight
Analysis and data insight RSS Feed RSS

Biopharmaceutical collaborations: February 2020

March 27, 2020
Biopharma licensings, joint ventures and collaborations, including: Achaogen, Advaxis, Aimmune, Aptevo, Aradigm, Astrazeneca, Atreca, Bicycle, Biogen, Caribou, Catalent, Cellectis, Cipla, Clover, Collegium, Curis, Cytodyn, Daewoong, Dyadic, Eisai, Evotec, Eyepoint, Genentech, Glenmark, Grifols, GSK, Hanmi, Hikma, Hollister, Hummingbird, Icagen, Immunos, Innocare, Janssen, Jounce, Karuna, Karyopharm, Kissei, Ligand, Luye, Medivir, Merck, Mylan, Nanostring, Norgine, Noxopharm, Otologic, Paratek, Pfizer, Portola, Probiogen, Redhill, Roche, Sangamo, Sarepta, Tetra, Trianni, Wize, Wockhardt, Wuxi, Xencor, Zeria, Zy.
Read More

Collaborations between biopharmaceutical companies and government/nonprofit entities: February 2020

March 27, 2020
Deals between biopharma companies and government or nonprofit entities, including: AB Biotics, ACT Genomics, Active Biotech, Active Motif, Agex, Be Cool, Benevolentai, Berg Pharma, Berkeley Lights, Beroni, Biomarin, Bridge, Cellular Biomedicine, Chugai, Cocrystal, Dianomi, Dyadic, Enochian, Entourage Phytolab, Erytech, Evgen, Exicure, FDA, Gemini, Generex, Genprex, Gibson Oncology, Gilead Sciences, GSK, Innovation, J&J, Medigen, NIH, Novartis, Oncologie, Orgenesis, Sanofi Pasteur, Sapphire, Synspira, Theratechnologies, Toa Eiyo, Tonix, VBL, Venturis, WPD.
Read More
Rare disease illustration

Gene and cell therapies being developed for rare diseases

March 23, 2020
By Peter Winter
The Rare Disease Day, which takes place at the end of February each year, is designed to focus global attention on the need for therapies to treat patients suffering from devastating rare diseases. The most recent event represented the 13th year it has been held. Over that period, research and development in the area has come a long way, and there are now 420 companies around the world that are active in developing regenerative medicines and advanced therapies for the treatment of rare diseases, according to a new report released by the Alliance for Regenerative Medicine (ARM).
Read More